Clinical Trials

MainTitle

Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings (NAMSAL)

This study has been completed
Sponsor
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)

Collaborator
Institut de Recherche pour le Developpement

Information provided by (Responsible Party)
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
ClinicalTrials.gov Identifier
NCT02777229

First received: March 1, 2016
Last updated: November 28, 2019
Last Verified: October 2019
History of Changes
Purpose

Purpose

Several reports indicate that treatment failure due to HIV resistance or to adverse event-related discontinuation could compromise the effectiveness of scaling-up antiretroviral treatment (ART), especially when lack of access to viral load is a concern. Combined with other nucleoside reverse transcriptase inhibitor, Dolutegravir (DTG) is a very promising alternative to the current first-line non nucleoside reverse transcriptase inhibitor-based regimens.

Initial evaluations of DTG conducted in high income countries showed excellent efficacy and safety and indicated high genetic barrier thus preserving second line treatment. As a consequence, DTG-based regimens have been recently included in the first-line options in the national guidelines for ART of several high-income countries. However, the clinical trials evaluating DTG-based regimens have been conducted in highly controlled conditions, including baseline resistance testing and regular viral load monitoring. Moreover, these trials included a high proportion of men with rare co-morbidities.

There is need to evaluate how a DTG-based regimen will perform in real-world conditions within resources-constrained settings, where viral load monitoring is limited, and where the majority of HIV patients are women with important family planning consideration and NAMSAL trial is a randomized clinical trial which aims to evaluate efficacy and safety over 48 weeks of DTG + tenofovir disoproxil fumarate/lamivudine versus Efavirenz (EFV) + tenofovir disoproxil fumarate/lamivudine in 606 ART-naïve HIV-1-infected adults in Cameroon. A set of efficacy and safety endpoints will be compared over 48 weeks between the two arms including the proportion of patients with viral load <50 copies/mL and incidence of severe adverse events.

Condition Intervention Phase
HIV-1 Infection

Drug : Dolutegravir 50 mg
Drug : Tenofovir disoproxil fumarate 300 mg / lamivudine 300 mg
Drug : Efavirenz 200 mg
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase III Randomized, Open Label Trial to Evaluate Dolutegravir Versus Efavirenz 400 mg, Both Combined With Tenofovir Disoproxil Fumarate + Lamivudine for the Initial Management of HIV Infected Adults in Resource-limited Settings

Further study details as provided by French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS):

Primary Outcome Measures

  • Proportion of patients with Viral Load (VL) <50 cp/mL at week 48 (FDA snapshot algorithm) [ Time Frame: week 48 ]
  • Proportion of patients with Viral Load (VL) <50 cp/mL at week 96 (FDA snapshot algorithm) [ Time Frame: week 96 ]
Secondary Outcome Measures:
  • Proportion of patients with VL< 50 cp/mL (FDA snapshot algorithm) [ Time Frame: week 24 ]
  • Proportion of patients with VL< 200 cp/mL (FDA snapshot algorithm) [ Time Frame: week 24, week 48, week 96 ]
  • Time to virologic failure [ Time Frame: 48 weeks, 96 weeks ]
  • Changes in Cluster of differentiation 4 (CD4)-cell count from Baseline [ Time Frame: Baseline, 48 weeks, 96 weeks ]
  • Time to death or to disease progression [ Time Frame: up to 48 weeks, 96 weeks ]
  • Time to first toxicity failure [ Time Frame: up to 48 weeks, 96 weeks ]
  • Incidence of first grade 3 or 4 clinical adverse event [ Time Frame: up to 48 weeks, 96 weeks ]
  • Incidence of first grade 3 or 4 laboratory adverse event [ Time Frame: up to 48 weeks and 96 weeks ]
  • Incidence of adverse events (AE) and serious adverse event (SAE) [ Time Frame: up to 48 weeks and 96 weeks ]
  • Time to treatment discontinuation [ Time Frame: 48 weeks, 96 weeks ]
  • Changes in hemoglobin from Baseline [ Time Frame: Baseline,48 weeks, 96 weeks ]
  • Changes in creatinine from Baseline [ Time Frame: Baseline,48 weeks, 96 weeks ]
  • Changes in estimated glomerular filtration rate from Baseline [ Time Frame: Baseline,48 weeks, 96 weeks ]
  • Changes in Aspartate Aminotransferase (AST) from Baseline [ Time Frame: Baseline,48 weeks, 96 weeks ]
  • Changes in Alanine Aminotransferase (ALT) from Baseline [ Time Frame: Baseline,48 weeks, 96 weeks ]
  • Changes in level of fasting glucose from Baseline [ Time Frame: Baseline,48 weeks, 96 weeks ]
  • Changes in level of total cholesterol from Baseline [ Time Frame: Baseline,48 weeks, 96 weeks ]
  • Changes in level of triglycerides from Baseline [ Time Frame: Baseline,48 weeks, 96 weeks ]
  • Changes in level of HDL from Baseline [ Time Frame: Baseline,48 weeks, 96 weeks ]
  • Proportion of patients defaulting clinic schedule [ Time Frame: 48 weeks, 96 weeks ]
  • Mean adherence level overall [ Time Frame: 48 weeks, 96 weeks ]
  • Mean change in Depression Anxiety Stress Scale [ Time Frame: Baseline,48 weeks, 96 weeks ]
  • Mean change in Quality of life score assessed by the Short Form health survey [ Time Frame: Baseline,48 weeks, 96 weeks ]
    composite score
  • Mean change in EFV-related symptoms questionnaire score [ Time Frame: Baseline,48 weeks, 96 weeks ]
    composite score

Enrollment: 616
Study Start Date: July 2016
Study Completion Date: August 2019
Primary Completion Date: July 2018 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
Experimental: Dolutegravir
Dolutegravir 50 mg Quaque die (QD) + tenofovir disoproxil fumarate/lamivudine 300 mg/ 300 mg Fixed Dose Combination (FDC) QD
Drug: Dolutegravir 50 mg

1 tablet once a day

Drug: Tenofovir disoproxil fumarate 300 mg / lamivudine 300 mg

Fixed dose combination, 1 tablet once a day

Active Comparator: Efavirenz
Efavirenz 400 mg QD + tenofovir disoproxil fumarate/lamivudine 300 mg/ 300 mg FDC QD
Drug: Tenofovir disoproxil fumarate 300 mg / lamivudine 300 mg

Fixed dose combination, 1 tablet once a day

Drug: Efavirenz 200 mg

2 tablets once a day

Eligibility

Eligibility

Ages Eligible for Study: 18 Years and older  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No  

Criteria

Inclusion Criteria:

  • HIV-1 infected
  • Age ≥ 18 years
  • Abtiretroviral-naïve, including above 7 days of cumulative prior antiretroviral therapy at any time prior to study entry.
  • For women of childbearing potential: acceptance to use effective contraceptive methods
  • Provision of written informed consent


Exclusion Criteria:
  • Infection with HIV-1 group O, N, P
  • Infection or co-infection with HIV-2
  • Absolute neutrophil count (ANC) < 500 cells/mm3
  • Hemoglobin < 7.0 g/dL
  • Platelet count < 50,000 cells/mm3
  • AST and/or ALT > 5 x Upper Limit of Normal (ULN)
  • Calculated creatinine clearance < 50 mL/min
  • Active opportunistic or severe disease not under adequate control
  • For women of childbearing age : Pregnancy/breastfeeding
  • History or presence of allergy and/or contraindications to the trial drugs or their components
  • Severe psychiatric illness
  • Severe hepatic failure Patients co-infected with tuberculosis (TB), receiving a TB
treatment and with stable clinical condition will not be excluded.

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02777229

Locations

Cameroon
Cité verte Hospital
Yaoundé, Cameroon
Hopital Central
Yaoundé, Cameroon
Military Hospital
Yaoundé, Cameroon

Sponsors and Collaborators

French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Institut de Recherche pour le Developpement

Investigators

Principal Investigator: Eric Delaporte, MD, PhD IRD, INSERM, University Montpellier
Principal Investigator: Charles Kouanfack, MD, PhD Central Hospital
More Information

More Information


Responsible Party: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)  
ClinicalTrials.gov Identifier: NCT02777229   History of Changes  
Other Study ID Numbers: ANRS 12313 NAMSAL  
Study First Received: March 1, 2016  
Last Updated: November 28, 2019  

Additional relevant MeSH terms:
Tenofovir
Lamivudine
Efavirenz
Dolutegravir

ClinicalTrials.gov processed this data on June 02, 2020
This information is provided by ClinicalTrials.gov.